Aura Biosciences (NASDAQ:AURA – Get Free Report) and Elevation Oncology (NASDAQ:ELEV – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Valuation & Earnings
This table compares Aura Biosciences and Elevation Oncology’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aura Biosciences | N/A | N/A | -$76.41 million | ($1.92) | -3.98 |
| Elevation Oncology | N/A | N/A | -$45.70 million | ($1.53) | -2.61 |
Aura Biosciences is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Insider & Institutional Ownership
96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 5.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 14.9% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Aura Biosciences and Elevation Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aura Biosciences | N/A | -42.20% | -36.66% |
| Elevation Oncology | N/A | -72.76% | -43.15% |
Analyst Recommendations
This is a breakdown of current ratings for Aura Biosciences and Elevation Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aura Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| Elevation Oncology | 0 | 0 | 5 | 0 | 3.00 |
Aura Biosciences currently has a consensus target price of $21.00, indicating a potential upside of 174.51%. Elevation Oncology has a consensus target price of $7.25, indicating a potential upside of 81.25%. Given Aura Biosciences’ higher possible upside, equities research analysts clearly believe Aura Biosciences is more favorable than Elevation Oncology.
Summary
Elevation Oncology beats Aura Biosciences on 6 of the 10 factors compared between the two stocks.
About Aura Biosciences
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
About Elevation Oncology
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
